- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03756311
Expanded Access to NanoPac
November 7, 2023 updated by: NanOlogy, LLC
NanOlogy may consider offering expanded access to NanoPac for patients who do not meet the enrollment criteria of clinical trials in progress.
Study Overview
Status
Available
Intervention / Treatment
Study Type
Expanded Access
Expanded Access Type
- Individual Patients
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Gere diZerega, MD
- Phone Number: 805-595-1300
- Email: gere.dizerega@usbiotest.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Description
Inclusion Criteria:
-
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 26, 2018
First Submitted That Met QC Criteria
November 26, 2018
First Posted (Actual)
November 28, 2018
Study Record Updates
Last Update Posted (Actual)
November 8, 2023
Last Update Submitted That Met QC Criteria
November 7, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NANOPAC-EA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NanoPac (sterile nanoparticulate paclitaxel) Powder for Suspension
-
NanOlogy, LLCUS Biotest, Inc.Active, not recruitingLung Cancer | Lung Cancer, Nonsmall Cell | Neoplasm of Lung | Lung Cancer, Small CellUnited States
-
NanOlogy, LLCUS Biotest, Inc.TerminatedUrogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer AdenocarcinomaUnited States
-
NanOlogy, LLCUS Biotest, Inc.WithdrawnKidney Cancer | Renal Cell Carcinoma | Renal Cell Cancer | Adenocarcinoma of Kidney | Adenocarcinoma, Renal
-
Steno Diabetes Center CopenhagenZealand University Hospital; AstraZenecaUnknownType 2 Diabetes Mellitus With Kidney ComplicationsDenmark
-
Vifor Fresenius Medical Care Renal PharmaTigermed Consulting Co., LtdRecruitingRenal Insufficiency, Chronic | HyperkalemiaChina
-
Medicines for Malaria VentureAbbVieTerminatedHealthy Volunteers | BioavailabilityUnited States
-
GlaxoSmithKlineCompleted
-
PfizerRecruitingShingles | Human | Herpes Zoster InfectionUnited States
-
PT. Medisafe TechnologiesCompleted